Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | FASN | P49327 | 5/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207291 | 0.89 | FASN (0.53) | FASN | |
| SCHEMBL4738617 | 0.88 | PARP10 (0.45) | PARP10PARP14ALDH1A1FASNNAMPT | |
| SCHEMBL4738015 | 0.87 | PARP10 (0.46) | PARP10PARP14ALDH1A1FASNNAMPT | |
| SCHEMBL4193256 | 0.80 | FASN (0.51) | FASN | |
| SCHEMBL4199222 | 0.77 | FASN (0.45) | PARP10FASN | |
| SCHEMBL4199414 | 0.77 | FASN (0.54) | FASN | |
| SCHEMBL4202879 | 0.76 | FASN (0.55) | FASN | |
| SCHEMBL4199547 | 0.76 | FASN (0.53) | FASN | |
| SCHEMBL4191753 | 0.75 | PARP10 (0.58) | PARP10PARP14ALDH1A1FASNNAMPT | |
| SCHEMBL4204850 | 0.75 | PARP14 (0.42) | PARP10PARP14ALDH1A1FASNHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | GPR119, FABP4, FASN | PARP10 1851/4885PARP14 1838/4885ALDH1A1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.